RxDoctor Payments Data

Wallace Lai, MD

Clinical Cardiac Electrophysiology · Salem, ORNPI 1578503249

Payments from drug & device makers

What this record shows

This record is dominated by other: $4,875 of the $7,720 with a category attached, or 63.1%. Angiodynamics, Inc. accounts for 63.1% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $5,177 and has fallen 92.7% since, to $375 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in OR, where the typical reported total is $7,720.

$7,720in general payments, 2019–2025

Across 135 payments — averaging $57.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$5K
  • Novartis$618
  • Johnson & Johnson$328
  • Boston Scientific$226
  • Medtronic$213
  • Bard Peripheral Vascular, Inc.$184
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,84537%
  • Other$4,87563%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,720 in reported general payments places this provider in the 50th percentile of 37 clinical cardiac electrophysiology providers in Oregon.

See all clinical cardiac electrophysiology providers in Oregon

Medicare billing

Part B allowed, 2024
$215,240
Medicare patients
556
Services billed
1,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban543$566,652
XareltoRivaroxaban113$131,014
EntrestoSacubitril/Valsartan41$44,873
FarxigaDapagliflozin Propanediol30$19,047
Flecainide Acetate234$10,025
Metoprolol Succinate478$7,612
Potassium Chloride113$3,280
Torsemide92$2,524
Amiodarone Hcl165$2,305
Atorvastatin Calcium233$2,272
SotalolSotalol Hcl84$1,718
Losartan Potassium111$1,711
Furosemide238$1,697
Carvedilol112$1,542
Amlodipine Besylate140$1,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$566,652543 claims
Johnson & JohnsonXarelto$328$131,014113 claims
NovartisEntresto$618$44,87341 claims
AstraZenecaFarxiga$109$19,04730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 37 clinical cardiac electrophysiology providers in Oregon.

Other clinical cardiac electrophysiology in Salem

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →